Revvity (RVTY) Investor Day 2024 summary

Strategic transformation and portfolio evolution

• Shifted from a diversified business to a focused life sciences and diagnostics company, divesting non-core segments and acquiring key assets like BioLegend and Euroimmun to address large molecule and immunodiagnostics markets.

• Recurring revenue now represents 80% of total, with a strong presence in high-growth end markets and a differentiated financial profile.

• Operating margin improved from 20% to nearly 30%, and adjusted free cash flow conversion increased to over 85%.

• New operating structure consolidates applied genomics into life sciences, effective 2025, to enhance commercial and operational synergies.

• Portfolio now positioned to support megatrends like cell/gene therapy, precision medicine, and AI-enabled solutions.

Growth drivers and innovation focus

• Life sciences solutions business expected to grow 6%-8%, driven by reagents, instruments, and software, with innovation in areas like AI, automation, and multi-omics.

• Immunodiagnostics and software segments forecasted to grow 9%-11%, supported by recurring revenue and new product launches.

• Expansion into GMP bioprocessing and adjacent markets contributes roughly 100 basis points to growth, with a focus on customer-driven product development.

• SaaS transition in software business enables double-digit growth, high retention, and broader market access, especially for tier-two and material science customers.

• Internal collaboration and insourcing (e.g., antibodies, oligos) drive cost savings, product development speed, and margin expansion.

Financial outlook and capital allocation

• Reaffirmed long-range targets: 6%-8% organic growth, 75 basis points annual operating margin expansion, and free cash flow conversion above 85%.

• Margin expansion driven by mix shift to higher-margin businesses, operational efficiencies, and digitalization.

• Capital deployment balanced between M&A and share repurchases, with $1 billion new authorization and focus on bolt-on acquisitions to fill strategic gaps.

• China exposure is 17% of revenue; local manufacturing and supply chain redundancies mitigate geopolitical risks.

• Pricing strategies harmonized within business units, leveraging scale and innovation to maintain or improve margins without frequent price increases.